Topoisomerase IIα (TOP2A) recently has been identified as an overexpressed gene product in pancreatic adenocarcinoma. 1 TOP2A functions to catalyze the unwinding of supercoiled DNA molecules for efficient DNA replication during cellular proliferation. 2 Expression of TOP2A has been described in tissues containing a predominant proliferating cell population, such as proliferating endometrium and spermatocytes, rather than in terminally differentiated cells, 3 and expression has been shown to correlate with cyclin A levels in acute lymphoblastic leukemia. 4 In certain cancer types, such as breast cancer and acute myeloid leukemia, however, increased TOP2A expression occurs secondary to gene amplification rather than transcriptional activation. 5, 6 TOP2A is situated at the long arm of chromosome 17 (17q21-q22) in proximity to the well-characterized protooncogene human epidermal growth factor receptor (HER)2/neu (17q11.2-q12). Amplification of HER2/neu, which encodes a receptor tyrosine kinase, has been described in a number of cancer types, including breast, ovarian, and pancreatic, 7-10 and has been associated with a poor prognosis in breast cancer. 11 In many cases, TOP2A and HER2/neu are coamplified during carcinogenesis, 12 suggesting a possible functional relationship between these genes.
We sought to identify the frequency of amplification of the topoisomerase IIα gene
Topoisomerase IIα (TOP2A) recently has been identified as an overexpressed gene product in pancreatic adenocarcinoma. 1 TOP2A functions to catalyze the unwinding of supercoiled DNA molecules for efficient DNA replication during cellular proliferation. 2 Expression of TOP2A has been described in tissues containing a predominant proliferating cell population, such as proliferating endometrium and spermatocytes, rather than in terminally differentiated cells, 3 and expression has been shown to correlate with cyclin A levels in acute lymphoblastic leukemia. 4 In certain cancer types, such as breast cancer and acute myeloid leukemia, however, increased TOP2A expression occurs secondary to gene amplification rather than transcriptional activation. 5, 6 TOP2A is situated at the long arm of chromosome 17 (17q21-q22) in proximity to the well-characterized protooncogene human epidermal growth factor receptor (HER)2/neu (17q11.2-q12). Amplification of HER2/neu, which encodes a receptor tyrosine kinase, has been described in a number of cancer types, including breast, ovarian, and pancreatic, [7] [8] [9] [10] and has been associated with a poor prognosis in breast cancer. 11 In many cases, TOP2A and HER2/neu are coamplified during carcinogenesis, 12 suggesting a possible functional relationship between these genes.
Characterization of neoplasms for TOP2A or HER2/neu expression, copy number, or activity frequently is performed to identify potential chemotherapeutic regimens that could target specifically the molecular alterations within cancer cells. 13 Alteration of HER2/neu levels has been shown to alter the sensitivity of cancer cells to specific chemotherapeutic regimens, such as TOP2A inhibitors (anthracyclines), [14] [15] [16] although this might reflect, in part, TOP2A amplification or deletion as a consequence of HER2/neu gene amplification. 17 Recently, increased levels of TOP2A transcripts (5.28-fold increase; P < .0001) have been identified in pancreatic adenocarcinoma specimens compared with normal pancreatic tissue using complementary DNA and oligonucleotide array technology. 1 By using immunolabeling analysis, we confirmed increased expression of the TOP2A protein in pancreatic cancer specimens relative to normal pancreatic ductal epithelium. To determine whether the expression of TOP2A in pancreatic adenocarcinoma is due to transcriptional overexpression or gene amplification, we used the new LSI TOP2A/LSI HER2/CEP 17 DNA fluorescence in situ hybridization (FISH) technique to determine the copy number of TOP2A and HER2/neu in paraffin-embedded tissue sections. We report the first demonstration of TOP2A amplification in a subset of pancreatic cancer specimens and frequent coamplification of TOP2A and HER2/neu within these lesions. We propose that a combination of TOP2A immunolabeling and multiprobe FISH analysis on TOP2A-positive cancers with a nuclear labeling index (NLI) of 25% or more might be a potentially useful modality for determining potential chemotherapeutic regimens for patients with pancreatic adenocarcinoma.
Materials and Methods

Study Material
Permission for the study was obtained from the Johns Hopkins Joint Committee for Clinical Investigation (Baltimore, MD). Paraffin-embedded material from a series of 55 pancreatectomies containing pancreatic ductal adenocarcinoma resected at the Johns Hopkins Hospital between June 1996 and September 2001 were used for the immunohistochemical portion of this study. A subset of these neoplasms (32 specimens) was analyzed further by using multiprobe FISH analysis for HER2/neu and TOP2A copy numbers. The average primary tumor diameter was 3.5 cm (range, 1.5-14.5 cm). The average patient age was 66 years.
Immunohistochemical Analysis
We used 3-to 4-µm sections from paraffin-embedded tissue samples for immunohistochemical analysis. Slides were deparaffinized in fresh xylene and rehydrated through sequential graded ethanol steps. Antigen retrieval was performed by citrate buffer incubation (0.1-mmol/L concentration of stock, pH 6) using a household vegetable steamer (Black and Decker, Shelton, CT) for 60 minutes. Slides were incubated for 5 minutes with 3% hydrogen peroxide, washed in tris(hydroxymethyl)aminomethane (Tris)-buffered saline/polysorbate (20-mmol/L concentration of Tris, 140-mmol/L concentration of sodium chloride, 0.1% polysorbate 20, pH 7.6), and incubated in appropriate antibody dilution for TOP2A (1:3,200, clone TG100, NeoMarkers, Fremont, CA) for 60 minutes at room temperature. The avidin-biotin-peroxidase complex method (DAKO, Carpinteria, CA) was used to visualize antibody binding. The peroxidase reaction was catalyzed using 3,3'-diaminobenzidine tetrahydrochloride (0.5 mg/mL final solution) and hydrogen peroxide (0.5%) as substrates. Slides subsequently were counterstained with hematoxylin.
TOP2A Immunohistochemical Analysis
TOP2A-stained slides from 55 pancreatic cancer specimens were examined, and positive nuclei were scored independently by 3 observers (D.E.H., R.E.W., A.M.) using an Olympus BX-41 microscope (Olympus Optical, Tokyo, Japan). Adjacent pancreatic intraepithelial neoplastic (PanIN) lesions, when present, also were analyzed and scored. The TOP2A NLI was determined by assessing the proportion of positive nuclei within a neoplasm using a representative neoplastic region (positive nuclei/total nuclei × 100). In total, approximately 200 cells were assessed per region, which yielded a reproducible result with minimal variance and, therefore, was used for all samples. A subset of these lesions subsequently was used for FISH analysis, and the properties of these lesions are listed in ❚Table 1❚.
LSI TOP2A/LSI HER2/CEP 17 Multicolor Probe FISH Analysis
In total, 32 pancreatic cancer specimens demonstrating a range of TOP2A NLI were used for FISH analysis. The newly designed multicolor probe against TOP2A/HER2/CEP 17 from Vysis (Downers Grove, IL) was used to assess the copy number of TOP2A (17q21-q22) and HER2/neu (17q11.2-q12). The CEP 17 probe, which hybridizes to the α satellite DNA at 17p11.1-q11.1, was used as a chromosomal copy number control. Probe labeling was as follows: TOP2A, SpectrumOrange; HER2/neu, SpectrumGreen; and CEP 17, SpectrumAqua.
All levels for TOP2A and HER2/neu are reported as a gene/CEP 17 ratio to standardize to the total chromosome number present within pancreatic cancer cells. Low-level amplification was defined as a gene/CEP 17 ratio of 1.8 to 2.2, and highlevel amplification was defined as a gene/CEP 17 ratio of more than 2.2. FISH labeling was performed according to the Vysis protocol and as described previously. 18 Briefly, hybridization buffer, DNA probe, and purified water were combined, centrifuged, and heated to 73°C for 5 minutes in a water bath. Slides were immersed in a denaturant bath (70% formamide/2× standard saline citrate) for 5 minutes at 73°C, followed by dehydration in increasing ethanol concentrations, and then dried. Probe mix was applied to each slide, and slides were placed in a 42°C incubator for 30 minutes. Slides subsequently were washed in 0.4× standard saline citrate/0.3% NP-40 for 2 minutes, air dried in darkness, counterstained with DAPI, and coverslipped.
Analysis of TOP2A amplification was performed by comparison with NLI in these lesions. The Fisher exact test was used to identify a significant difference in the presence of TOP2A amplification with a cutoff of less than 25% vs 25% or more, which is higher than a previously described TOP2A cutoff in other lesions. 20 
Results
TOP2A Protein Was Detectable in All Pancreatic Adenocarcinomas Examined
Because TOP2A was identified as an up-regulated transcript in pancreatic adenocarcinomas by complementary DNA and oligonucleotide analysis, 1 we initially sought to confirm increased TOP2A gene product in these cancers. By using 55 pancreatic ductal adenocarcinoma specimens and matched normal pancreatic tissue adjacent to the neoplasm, we performed immunolabeling analysis using an antibody directed against TOP2A. Nuclear immunolabeling for TOP2A was evident in all carcinoma specimens examined ❚Image 1❚, and an NLI was assigned to all lesions. The NLI varied from 5% to 80%.
Normal pancreatic ductal epithelium has been proposed to give rise to pancreatic adenocarcinoma, 20 and, therefore, we examined 55 regions adjacent to these pancreatic cancers to determine baseline expression of TOP2A in ductal epithelial cells. In all 55 cases, no detectable nuclear immunolabeling for TOP2A was apparent (data not shown). Of these adjacent regions, 30 also contained associated PanIN lesions 20 To determine whether the TOP2A expression evident in pancreatic ductal adenocarcinomas was a result of gene amplification or increased transcription due to cellular proliferation, we performed FISH analysis to determine the TOP2A copy number in a subset of 32 specimens with an NLI ranging from 5% to 80%. Because TOP2A is situated telomeric to the HER2/neu oncogene and both TOP2A and HER2/neu have been described as being coamplified in a number of cancers, 12 we used the newly developed multicolor probe against TOP2A and HER2/neu to determine the overall copy numbers of these genes. Amplification of TOP2A (TOP2A/CEP 17 ratio, ≥1.8) was identified in 9 lesions, which demonstrated a TOP2A NLI of 5%, 20%, 25%, 40% (3 lesions), 50% (2 lesions), and 80% ❚Figure 1❚.
Of 14 lesions with a TOP2A NLI less than 25%, amplification of TOP2A (TOP2A/CEP 17 ratio, ≥1.8) was detectable in 2 lesions (14%), although 1 of these lesions demonstrated a borderline ratio of exactly 1.80. In contrast, of 18 lesions with a TOP2A NLI of 25% or more, TOP2A amplification was present in 7 (39%) ❚Table 2❚. A Student t test comparing the TOP2A amplification scores between the populations with an NLI of less than 25% and an NLI of 25% or more revealed a significant difference (Table 2) . In specimens that did not demonstrate TOP2A amplification, increased TOP2A expression might be secondary to the increased proliferation level present in these cancers, although further study is necessary to determine whether this is the case. In total, 28% (9/32) of all pancreatic cancer specimens demonstrated TOP2A gene amplification, and 78% (7/9) demonstrated a TOP2A immunolabeling NLI of 25% or more. Furthermore, the negative predictive value (NPV) of a TOP2A NLI of less than 25% for TOP2A amplification was 86%, suggesting that TOP2A immunolabeling and quantification with a 25% NLI cutoff might be a useful primary screening strategy to assess patient specimens for TOP2A amplification.
By using an NLI of 25% or more, we categorized the original 55 cancer specimens as high expressors (19 specimens with an NLI of ≥25%) and low expressors (36 specimens with an NLI of <25%; Table 2 ). The range of nuclear labeling ranged from 5% (3 specimens) to 80% (3 specimens). No significant correlation was apparent between the TOP2A NLI and metastases or vascular invasion (Table 1) .
HER2/neu Frequently Was Coamplified With TOP2A in Pancreatic Cancers
Because HER2/neu resides in proximity to TOP2A on chromosome 17 and HER2/neu occasionally can be coamplified with TOP2A in primary cancers and cancer cell lines, 12, 13 we assessed the previous subset of 32 pancreatic cancers for coamplification of these 2 genes. HER2/neu has been described as amplified in a subset of pancreatic cancers, 9 although coamplification of TOP2A in these cases is unknown. By using the LSI TOP2A/LSI HER2/CEP 17 multicolor probe, we identified the copy numbers of TOP2A (orange), HER2/neu (green), and chromosome 17 number (CEP 17, aqua) ❚Image 2❚.
Of the 2 lesions with a TOP2A NLI of less than 25% and 
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coamplification (copy number, 2.36) ❚Table 3❚. The 7 pancreatic cancer lesions with a TOP2A NLI of 25% or more that demonstrated TOP2A amplification also demonstrated predominantly concordant low-level (3 cases) or high-level (3 cases) amplification of HER2/neu. Only 1 of the 7 cases demonstrated a high-level TOP2A amplification (copy number, 2.33) and low-level HER2/neu amplification (copy number, 2.13). The overall population difference between less than 25% TOP2A NLI and 25% or more TOP2A NLI also was significant (Table 2 ). In summary, of 9 cases of pancreatic cancer demonstrating TOP2A amplification, 8 (89%) contained coexistent HER2/neu amplification. Furthermore, the specificity of TOP2A for HER2/neu coamplification using TOP2A as a probe was 96% (NPV, 100%). Because TOP2A and HER2/neu coamplification has been shown to affect prognosis and chemotherapeutic efficacy in other cancer types, multicolor probe FISH analysis of TOP2A and HER2/neu gene copy numbers, or analysis of TOP2A amplification alone, might be a useful modality for screening patients with a demonstrated TOP2A nuclear immunolabeling index of 25% or more.
Discussion
TOP2A functions as a key enzyme in DNA replication to promote the efficient unwinding of supercoiled DNA molecules. Increases in TOP2A expression are associated with normal cellular proliferation, and increased levels of TOP2A protein have been described in esophageal, bladder, and breast cancers, among others. 6, 19, 21 The overexpression of TOP2A in various cancer types has led to the development of TOP2A-specific inhibitors (anthracyclines), 2, 22 which have been used successfully as adjuvant therapy in specific cancers, such as breast adenocarcinoma. 23 To the best of our knowledge, this is the first report of TOP2A amplification in pancreatic cancer. Of 32 pancreatic cancer specimens examined by FISH analysis in our study, 9 of these (28%) demonstrated TOP2A amplification.
TOP2A is situated in proximity to HER2/neu on human chromosome 17. Amplification of TOP2A generally is associated with coamplification of HER2/neu, 23, 24 although the converse frequently does not hold. HER2/neu encodes a tyrosine kinase receptor that is amplified in many cancer types, including breast and pancreatic cancer. 8, 9 Increased levels of HER2/neu amplification seem to correlate with increasing cancer stage in ovarian lesions 25 and to serve as a positive predictive marker of response to the therapeutic anti-HER2/neu antibody trastuzumab in breast cancer. [26] [27] [28] In breast cancer, HER2/neu amplification has been associated with amplification, deletion, or unchanged copy number of TOP2A. 12 In cancers demonstrating HER2/neu amplification, HER2/neu can be used as a positive predictive marker for response to TOP2A-inhibitor adjuvant therapy when associated with TOP2A coamplification. 17, 29, 30 In the present study, we identified an 89% concordance rate for TOP2A/HER2/neu amplification in pancreatic cancer, indicating that these 2 genes frequently are coamplified in this disease. In 1 case which only TOP2A amplification was evident, the TOP2A copy number was borderline for our criteria of amplification (copy number, 1.80). In addition to examining TOP2A expression in pancreatic cancers, we also performed immunolabeling for HER2/neu on the subset of pancreatic cancers selected for FISH analysis (data not shown). Although 8 of 32 pancreatic adenocarcinomas demonstrated amplification of HER2/neu by FISH analysis, none of these cases demonstrated immunolabeling for the HER2/neu protein. Because previous studies frequently used HER2/neu immunolabeling as an entry criterion for studies on HER2/neu amplification and therapeutic outcomes using HER2/neu-or TOP2A-targeted strategies, 9 we propose that use of immunolabeling for the TOP2A gene product might be a more effective means of screening for TOP2A and HER2/neu amplification in this patient population.
The majority of patients in our study population demonstrated lymph node metastases and vascular invasion, but not liver metastases. Previous studies on breast cancer specimens have identified consistent alterations in TOP2A and HER2/neu amplification between the primary tumor and metastatic lesion. 24, 31 Furthermore, these amplifications have been used to identify subpopulations of cells within primary tumors that harbor similar genetic alterations within metastatic lesions. 31 In our study, we did not examine the status of TOP2A and HER2/neu amplifications in primary tumors vs metastases, although such a study might be useful to determine the evolution of the chromosome 17q amplicon in tumor progression and metastatic spread. We used a 2-step strategy for the identification of TOP2A and HER2/neu overexpression and amplification in pancreatic cancer specimens. Our initial assessment of cancer specimens used a rapid, cost-effective screen using an antibody against the TOP2A gene product to assess the percentage of positively labeled nuclei. In cases in which at least 25% nuclear immunolabeling was identified, multicolor probe FISH analysis identified TOP2A amplification in 39% of the specimens (7/18), with an NPV of 86%. In virtually all cases, TOP2A amplification was associated with HER2/neu coamplification (positive predictive value, 96%; NPV, 100%).
Our findings indicate that immunolabeling for the TOP2A protein, combined with LSI TOP2A/LSI HER2/CEP 17 FISH analysis, can effectively identify increased TOP2A and HER2/neu gene copy numbers in patients with pancreatic cancer, which might increase the likelihood of appropriate adjuvant therapy, such as TOP2A-inhibitors (anthracyclines) or HER2/neu-directed monoclonal antibodies (trastuzumab 32 ) or tyrosine kinase inhibitors. 33 Further analyses of cases with a TOP2A NLI of 25% or more by LSI TOP2A/LSI HER2/CEP 17 FISH should be performed to determine TOP2A and HER2/neu copy numbers in these specimens, which can therefore be used to direct the use of adjuvant therapy in patients with pancreatic cancer.
